Key result
Fenoldopam is a selective dopamine-1 receptor agonist that produces vasodilation, increases renal blood flow, and improves renal function in animal models of renal failure.
Fenoldopam is a selective DA1 receptor agonist that lowers blood pressure while maintaining or improving renal perfusion and function.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for fenoldopam in hypertensive renal disease; requires randomized human trials before any practice consideration.
Fenoldopam is a selective dopamine1 (DA1) receptor agonist. Most of the DA1 receptor agonist activity of fenoldopam resides in the R-enantiomer, which also shows weaker alpha 2-adrenoceptor antagonist activity Fenoldopam produces vasodilation in vascular beds that are rich in vascular DA1 receptors, eg, renal and mesenteric receptors, and produces an increase in renal blood flow at doses that do not affect blood pressure. At higher doses, fenoldopam lowers blood pressure but still maintains renal perfusion. In addition to its renal vasodilator activity, fenoldopam is natriuretic, possibly resulting from a direct effect of DA1 receptors on the proximal convoluted tubule. In animals with spontaneous or drug-induced renal failure, fenoldopam improves renal function.
No takes yet. Share an insight, caveat, or question.
Nichols et al. (1990) reported a review. Fenoldopam was evaluated. Fenoldopam is a selective dopamine-1 receptor agonist that produces vasodilation, increases renal blood flow, and improves renal function in animal models of renal failure.
Synapse has enriched 10 related papers. Consider them for comparative context: